Clinical Trial Update: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Infigratinib in gastric cancer or GEJ adenocarcinoma with FGFR2 amplification or other FGFR alterations; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: LianBio LLC | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN